Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
Immune checkpoint therapy is a new mode of tumor therapy. At present, many kinds of PD-1/PD-L1 inhibitors have been approved for clinical application on various tumors, such as malignant melanoma, lung cancer, bladder cancer, lymphoma, etc. However, with the gradual promotion and application in clin...
Guardado en:
Autores principales: | LAI Yanliang, GENG Yan, YANG Bingquan |
---|---|
Formato: | article |
Lenguaje: | ZH |
Publicado: |
Magazine House of Cancer Research on Prevention and Treatment
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d8ae6841853849339273588500c2bc99 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma
por: YU Xuxu, et al.
Publicado: (2021) -
Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea M, et al.
Publicado: (2021) -
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Utpal Kumar, et al.
Publicado: (2021) -
Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
por: Marina A. Lyadova, et al.
Publicado: (2021) -
Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Kimberly M. Burcher, et al.
Publicado: (2021)